drugset / Trial / NCT01218451
NeisVac-C Single Prime Study in Infants
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to assess the feasibility of a single priming dose of NeisVac-C in infants (at either 4 or 6 months of age), as determined by immune response.
Timeline
- Start
- 2010-09
- Primary completion
- 2012-01
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NeisVac-C | Vaccine | 0.5 ml | Subcutaneous |
| Background | Infanrix hexa | Vaccine | 0.5 ml | Subcutaneous |
| Background | Prevnar 13 | Vaccine | 0.5 ml | Subcutaneous |